Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 1;109(6):1984-1988.
doi: 10.3324/haematol.2023.284429.

Targeting CCR4 with mogamulizumab in refractory CD3-CD4+ lymphocytic-variant hypereosinophilic syndrome

Emmanuel Ledoult  1 , Matthieu Groh  2 , Bertrand Meresse  3 , Romain Dubois  4 , Jacques Trauet  5 , Elise Toussaint  6 , Marie Delbeke  3 , Eric Hachulla  7 , Louis Terriou  8 , Adèle De Masson  9 , Michele Vasseur  10 , Myriam Labalette  5 , David Launay  7 , Jean-Emmanuel Kahn  11 , Guillaume Lefevre  12
Affiliations

Targeting CCR4 with mogamulizumab in refractory CD3-CD4+ lymphocytic-variant hypereosinophilic syndrome

Emmanuel Ledoult et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Histologic findings, antibody-dependent cellular cytotoxicity results, and lymph node response to mogamulizumab. (A) Lymph node biopsy showing a benign infiltration of CCR4+CD4+ T cells. Left: hematoxylin and eosin staining x400 magnification, scale bar=50 µm. Right: immunostaining x100 magnification, scale bar=200 µm, anti-CD4 (upper panel), anti-CD8 (middle panel) and anti-CCR4 (lower panel). (B) Ability of mogamulizumab to induce antibody-dependent cellular cytotoxicity (ADCC) on sorting CD3-CD4+ T cells by conducting an ADCC in vitro assay in 2 lymphocytic-variant hypereosinophilic syndrome (L-HES) patients using sorted CD3-CD4+ T cells as targeted cells (T) and homologous sorted natural killer (NK) cells as effector cells (E). NK cells kill CD3-CD4+ T cells coated with mogamulizumab (10 µg/mL) in a dose-dependent manner. No significant lysis was observed without mogamulizumab (data not shown). (C) Positron emission tomography/computed tomography scan showing a large lymph node enlargement (arrows) in case #2: 8 weeks (W8) before starting mogamulizumab (left), at baseline (middle) and W8 after treatment onset (right). E/T: effector/target ratio.
Figure 2.
Figure 2.
Hematological response to mogamulizumab in four refractory lymphocytic-variant hypereosinophilic syndrome patients. pINF-α: pegylated interferon α; MEPO: mepolizumab; MOGA: mogamulizumab; OCS: oral corticosteroids, d: day.
See this image and copyright information in PMC

References

    1. Lefèvre G, Copin M-C, Staumont-Sallé D, et al. . The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype. Medicine (Baltimore). 2014;93(17):255-266. - PMC - PubMed
    1. Valent P, Klion AD, Roufosse F, et al. . Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes. Allergy. 2023;78(1):47-59. - PMC - PubMed
    1. Carpentier C, Verbanck S, Schandené L, et al. . Eosinophilia associated with CD3-CD4+ T cells: characterization and outcome of a single-center cohort of 26 patients. Front Immunol. 2020;11:1765. - PMC - PubMed
    1. Shi Y, Wang C. What we have learned about lymphocytic variant hypereosinophilic syndrome: a systematic literature review. Clin Immunol. 2022;237:108982. - PubMed
    1. Lefevre G, Copin MC, Roumier C, Aubert H, 2015. CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder. Haematologica. 2015;100(8):1086-1095. - PMC - PubMed

MeSH terms